Acamprosate Dosing
The standard dose of acamprosate is 666 mg (two 333 mg tablets) taken three times daily, with dose reduction to 333 mg three times daily for patients with moderate renal impairment (creatinine clearance 30-50 mL/min), and the medication is contraindicated in severe renal impairment (creatinine clearance ≤30 mL/min). 1
Standard Dosing Regimen
The FDA-approved dosing is straightforward:
- Normal renal function: 666 mg (two 333 mg tablets) three times daily
- Total daily dose: 1,998 mg (approximately 2 grams per day)
- Timing: Can be taken without regard to meals, though dosing with meals was used in clinical trials and may be suggested for patients who eat three regular meals daily 1
Treatment should begin as soon as possible after alcohol withdrawal once the patient achieves abstinence, and should be maintained even if relapse occurs 1.
Renal Impairment Adjustments
Because acamprosate undergoes no hepatic metabolism and is eliminated entirely renally 2, renal function is the critical determinant of dosing:
Moderate Renal Impairment (CrCl 30-50 mL/min)
- Reduced dose: 333 mg (one tablet) three times daily 1
- This represents a 50% dose reduction from standard dosing
Severe Renal Impairment (CrCl ≤30 mL/min)
- Contraindicated - do not use acamprosate 1
- The drug will accumulate to potentially toxic levels given its exclusive renal elimination
Mild Renal Impairment (CrCl >50 mL/min)
- No dose adjustment needed - use standard dosing
Important Clinical Considerations
Hepatic safety advantage: Acamprosate has a significant safety advantage in patients with alcohol-associated liver disease because it undergoes no hepatic metabolism and has no reported instances of hepatotoxicity 2. This contrasts with naltrexone and disulfiram, which undergo hepatic metabolism and carry hepatotoxicity concerns.
Pharmacokinetic profile:
- Steady-state is reached after 5-7 days of dosing 3
- Terminal elimination half-life is approximately 20-33 hours with enteric-coated tablets 3
- Not protein-bound and not metabolized 3
- Accumulation ratio at steady-state is approximately 2.4 3
Alternative dosing considerations: While a reduced frequency regimen (500 mg twice daily) has been shown to be bioequivalent to the traditional three-times-daily dosing in pharmacokinetic studies 4, this lacks clinical efficacy data and cannot be recommended as a primary regimen. The traditional three-times-daily dosing remains the evidence-based standard.
Common Pitfalls to Avoid
- Don't use in severe renal impairment - This is an absolute contraindication, not just a dose reduction scenario
- Don't forget to assess renal function before initiating - Calculate creatinine clearance, don't rely on serum creatinine alone
- Don't use as monotherapy - Acamprosate should always be part of comprehensive psychosocial treatment 1
- Monitor for depression/suicidality - Though infrequent, suicidal ideation and attempts were more common with acamprosate than placebo in trials (1.4% vs 0.5%) 1
- Don't assume efficacy in polysubstance abuse - Acamprosate's efficacy has not been adequately assessed in polysubstance abusers 1
The number needed to treat to prevent return to any drinking is approximately 12 for acamprosate 2, making it a moderately effective pharmacotherapy when combined with psychosocial interventions.